KOC
VYGR icon

Koss-Olinger Consulting’s Voyager Therapeutics VYGR Stock Holding History

Koss-Olinger Consulting’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,636
Closed -$134K – 211
2022
Q1 		$134K Sell
17,636
-2,141
-11% -$9.55K 0.02% 186
2021
Q4 		$54K Buy
+19,777
New +$67.5K 0.01% 211

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Koss-Olinger Consulting's VYGR Position: Q2 2022 in Review

Koss-Olinger Consulting sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 17,636 shares — an estimated $134K sold.

Koss-Olinger Consulting first reported a position in VYGR in Q4 2021 and held it in 2 quarters. The position peaked at $134K in Q1 2022. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

  • Koss-Olinger Consulting reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Koss-Olinger Consulting sold 17,636 Voyager Therapeutics shares in Q2 2022, an estimated $134K.
  • Koss-Olinger Consulting first reported a position in Voyager Therapeutics in Q4 2021 and held it in 2 quarters.
  • Koss-Olinger Consulting's Voyager Therapeutics position peaked at $134K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on Koss-Olinger Consulting's 13F filing for Q2 2022, filed 8 Jul 2022.